Table 4.

Other descriptive data collected in the EXERPHARMA trial

	Collection time points
Descriptive data
Aastrands test	0, 8 weeks
Observer-reported outcomes
Performance in exercise group
Exercise diary (progression, pain, exertion level)	During treatment
Patient-reported outcomes
Generic health measure
SF-36 acute v. 1.0 (95% CI)	0, 8, 52 weeks
Health economic evaluation
EQ-5D v. 1.0 (95% CI)	0, 8, 52 weeks
Adverse events
Adverse events questionnaire, change from baseline	0, 8 weeks
Adverse events text messages, number and types of incidents	During treatment
Drug use
Drug use diary, amount, intensity, and type	8 weeks
Drug use text message, numbers	During treatment
Assessment of treatment
Global perceived effect (GPE)	8, 52 weeks
Patient Acceptability Symptom State (PASS)	8, 52 weeks
Treatment since end of study treatment
Treatment questionnaire, amount, type, and duration	52 weeks